Psychiatry Research recently published Use of lisdexamfetamine dimesylate in treatment of executive functioning deficits and chronic fatigue syndrome: A double blind, placebo-controlled study, detailing the results of a clinical trial conducted by Joel L. Young, M.D.
In this trial, Young studied 26 adults with chronic fatigue syndrome over the course of 8 weeks. Half the subjects were treated with lisdexamfetamine dimesylate (LDX) and the other half were given placebo. Assessments gauging cognition, fatigue and generalized pain indicated that subjects treated with LDX fared better than the placebo-treated group. LDX (Vyvanse®) is an approved medication for the treatment of Attention Deficit/Hyperactivity Disorder.
Chronic Fatigue Syndrome affects 1 to 4 million individuals in the United States. Those affected suffer high rates of disability and depression. No FDA-approved treatment options currently exist for the treatment of this condition.
In response to Vice President Joe Biden's meeting with representatives from the video gaming industry on violent video games and violent acts, Dr. Young shares his thoughts on the topic in a recent interview with WWJ.
Click here to read the full story.
RCBM is currently involved in clinical trials on the following research topics: